The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often misleading users about FDA approval. Researchers identified over 70 websites with vague safety disclosures.

By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines,

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

ABC News chief medical correspondent Dr. Tara Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss.

A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what to know, per a neurologist.